Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

The use of neridronic acid or a salt thereof in the treatment of osteoarthritis is described. In particular, neridronic acid or a salt thereof has been shown to be able to reduce significantly the symptoms of osteoarthritis, such as pain and physical and mobility disabilities, as well as subchondral bone marrow lesions underlying the onset of such symptoms.

The use of neridronic acid or a salt thereof in the treatment of osteoarthritis is described. In particular, neridronic acid or a salt thereof has been shown to be able to reduce significantly the symptoms of osteoarthritis, such as pain and physical and mobility disabilities, as well as subchondral bone marrow lesions underlying the onset of such symptoms.

The present disclosure is directed to methods of treating fibrotic conditions by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

The composition and method of the invention relate to dental implant or orthognathic implant, graft materials and platelet-rich fibrin (PRF) applications in the field of dental and jaw health. The invention particularly relates to a therapeutic composition comprising at least one anti-sclerostin antibody and at least one anti dickkopf-1 antibody in combination for increasing osseointegration and accelerating healing in dental implantation and bone volume augmentation in filling of insufficient bone sites, and methods of local administration thereof.

The composition and method of the invention relate to dental implant or orthognathic implant, graft materials and platelet-rich fibrin (PRF) applications in the field of dental and jaw health. The invention particularly relates to a therapeutic composition comprising at least one anti-sclerostin antibody and at least one anti dickkopf-1 antibody in combination for increasing osseointegration and accelerating healing in dental implantation and bone volume augmentation in filling of insufficient bone sites, and methods of local administration thereof.